In one preclinical study, Dasatinib in combination with temozolomide more effectively increased the therapeutic efficacy of temozolomide than when dasatinib was combined with carboplatin or irinotecan. Researchers also used dasatinib to treat mice with glioblastoma and found that the drug significantly reduced tumor growth. These results strongly support the ongoing studies of dasatinib in the treatment of glioblastoma and provide a rationale for combination therapy with dasatinib and temozolomide. However, I was not able to find any completed studies in humans.
RTOG is conducting a study of dasatinib with radiation. In its consent it says: “Dasatinib is an investigational agent for the treatment of glioblastoma, although it has been approved by the Food and Drug Administration for another cancer type.”
Vanessa Milano, Yuji Piao, Tiffany LaFortune and John de Groot Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma Mol Cancer Ther February 1, 2009 8, 394
Du et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature Biotechnology. DOI:10.1038/nbt.1513.